The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan which expires April 30, 2015.
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $32.34 to $33.31, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a securi
ty holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever KYTHERA Biopharmaceuticals makes a similar move, sign up!